
































































































then	undergoes	 a	process	of	 reactivation	 twice	between	birth	 and	adulthood.	 The	
first	is	in	early	infant	life,	during	the	so-called	‘mini-puberty’,	and	the	second	after	a	
period	 of	 dormancy	 between	 the	 age	 of	 one	 and	 eight-to-nine	 years,	 during	 the	
onset	of	puberty	(1).	While	puberty	is	recognised	as	the	maturational	process	of	the	
reproductive	endocrine	system	that	results	in	achievement	of	adult	height	and	body	
proportion,	 in	 addition	 to	 development	 of	 the	 genital	 organs	 and	 the	 capacity	 to	
reproduce,	mini-puberty	 has	 also	 been	 increasingly	 recognised	 as	 vital	 for	 normal	
fertility	development	(2).	
Development	of	the	clinical	features	of	puberty	is	initiated	by	the	reactivation	of	the	
HPG	 axis	 after	 this	 relative	 quiescence,	 but	 the	 nature	 of	 the	 puberty	 ‘brake’	 that	
acts	on	the	axis	after	the	mini-puberty,	and	how	and	when	this	brake	is	released,	is	
not	well	understood.	Whilst	the	timing	of	pubertal	onset	varies	within	and	between	
different	 populations,	 it	 is	 a	 highly	 heritable	 trait	 with	 estimates	 of	 up	 to	 80%	 of	
individual	 variation	 being	 under	 genetic	 regulation	 (3).	 	 However	 despite	 strong	
heritability,	 the	 key	 genetic	 factors	 that	 determine	 human	 pubertal	 timing	 in	 the	
normal	 population	 and	 in	 cases	 of	 disturbed	 pubertal	 timing	 remain	 mostly	
unknown.		





genders,	 clear	 age	 cut-offs	 for	 normal	 pubertal	 development	 have	 been	 drawn.	







gonadotropin-releasing	 hormone	 (GnRH)	 deficiency,	 such	 as	 in	 idiopathic	
hypogonadotropic	 hypogonadism	 (IHH),	 both	 fetal	 and	 postnatal	 pituitary	
gonadotropin	secretion	is	 low.	 In	males	during	fetal	 life,	placental	human	chorionic	
gonadotropin	(hCG)	stimulates	the	testis,	resulting	in	masculinization	of	the	external	
genitalia.	 However,	 later	 in	 fetal	 life,	 when	 hCG	 concentration	 in	 fetal	 circulation	
falls,	 luteinizing	 hormone	 (LH)	 stimulates	 further	 penile	 growth	 and	 testicular	
descent.	Consequently,	boys	with	IHH	often	have	micropenis	and	cryptorchidism	at	
birth.	 It	 is	 important	 to	 consider	 the	 diagnosis	 of	 IHH	 in	 isolated	 congenital	
undescended	 testes	 (2).	 Primary	 hypogonadism	 may	 also	 present	 at	 birth	 with	
under-developed	 genitalia	 in	 male	 infants	 if	 the	 condition	 is	 gonadotropin	
dependent,	or	alternatively	as	ambiguous	or	female	genitalia	if	the	defect	is	of	early-
















































































































or	 an	 acquired	 central	 dysfunction	 secondary	 to	 irradiation,	 tumour	 or	 vascular	
lesion.	 A	 picture	 of	 IHH	with	 no	 associated	 anatomical	 or	 functional	 defect	 in	 the	
HPG	axis	 occurs	 in	 1-10	 cases	 per	 100,000	births.	 Because	of	 different	 causes	 and	
incomplete	 penetrance,	 there	 is	 a	 wide	 spectrum	 of	 phenotypes,	 ranging	 from	
complete	HH	with	lack	of	pubertal	development	to	a	partial	hypogonadism	with	an	
arrest	 of	 pubertal	 development,	 and	 even	 reversible	 HH	 in	 some	 patients	 post	
treatment	 (27).	 Despite	 recent	 advances,	 with	 over	 thirty	 genes	 linked	 to	 this	
disorder	 identified,	 the	 pathophysiological	 basis	 of	 HH	 in	 approximately	 50%	 of	
individuals	remains	unclear.	The	condition	may	be	due	to	failure	of	development	of	



















































































































A	 management	 strategy	 of	 ‘watchful	 waiting’	 may	 be	 appropriate	 in	 isolated	 DP,	
where	 pubertal	 onset	 is	 late	 but	 expected	 to	 occur	 spontaneously.	 However,	 this	
decision	should	be	 taken	 in	conjunction	with	 the	patient,	 taking	 into	consideration	
their	 concerns	 and	 expectations.	 One	major	 concern	 often	 raised	 by	 patients	 and	
their	 families	 is	 the	 effect	 of	 pubertal	 delay	 on	 both	 current	 and	 adult	 height.	
Patients	 with	 DP	 are	 often	 short	 compared	 with	 their	 peers,	 and	 this	 is	 often	
compounded	by	the	fact	that	many	have	pubertal	delay	combined	with	familial	short	
stature.	However,	reassurance	can	be	given	to	such	patients	as	usually	in	DP	an	adult	
height	 only	 slightly	 below	 the	 genetic	 height	 potential	 (target	 height)	 is	 reached;	
although	there	may	be	large	individual	variation	(69,	70).		
DP	 in	 adolescents	 can	 be	 associated	with	 significant	 anxiety	 about	 body	 image	 in	




beneficial	 (71,	 72).	 The	 link	 between	 DP	 and	 reduced	 academic	 performance,	
substance	misuse	and	behavioral	difficulties	is	less	well	established.	
In	 contrast,	 if	 “red	 flag”	 markers	 of	 hypogonadism	 are	 present	 or	 if	 endogenous	
gonadotropin-dependent	puberty	has	not	started	after	one	year	of	treatment,	then	
permanent	 HH	 and	 other	 diagnoses	 should	 be	 reconsidered.	 In	 such	 instances	
treatment	should	be	initiated	promptly	 in	order	to	optimise	skeletal	growth	and	to	




































the	use	of	a	primed	GH-provocation	 test,	 the	 treatment	of	GH-replete	DP	patients	
with	growth	hormone	remains	controversial:	it	has	been	approved	by	the	US	FDA	for	
the	 treatment	 of	 ISS	 and	 height	 SDS	 <	 2.25	 for	 age,	 but	 leads	 to	 only	 a	 modest	
increase	in	adult	height	and	its	use	is	not	recommended	(77,	78).		
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A	 further	 potential	 pharmacological	 target	 in	 short	 boys	 with	 DP	 is	 inhibition	 of	
estrogen	biosynthesis	from	androgens	with	aromatase	inhibitors	(79,	80).	Epiphyseal	
closure	 is	 dependent	 on	 estrogens	 and	 thus	 aromatase	 inhibitors	 (AIs)	 can	
potentially	act	to	extend	the	time	period	of	long	bone	growth.		Some	published	data	
supports	 this	possible	effect	of	AIs	 to	delay	bone	maturation	and	to	 increase	adult	
height	in	boys	with	short	stature	and/or	DP	(79,	80).		However,	despite	recent	data	






























































































































































































	 Before	term	 At	term	 At	2–6	months	
corrected	age	
Girls	 	 	 	
FSH	(IU/mmol	Cr)		 250	 13	 5	
LH	(IU/mmol	Cr)		 500	 10	 0.5	
Boys	 	 	 	
FSH	(IU/mmol	Cr)		 10	 3	 1.5	
















































	 Isolated	DP	 Hypogonadism	 	
















































































































































































Norethisterone	 	 5mg		 More	androgenic,	increased	risk	
of	dysmenorrhoea	
Utrogestan	 	 200mg	once	daily	 	
Medroxyprogesterone	
acetate		
	 5mg	once	daily	 	
Combination	
preparations		
	 e.g.	Evorel	sequi,	Elleste-
Duet		
	
	
Treatment	of	Fertility	in	Women	
Pulsatile	GnRH	
s.c.	pump	
Not	applicable	 	 Requires	extensive	experience,	treatment	only	
within	specialist	centres.	Most	physiological	
form	of	replacement.	
hCG	(SC	or	IM)	plus	
recombinant	FSH	(SC).	
	
		
Not	applicable	 		 Requires	extensive	experience,	treatment	only	
within	specialist	fertility	centres	
	
*	adjustments	for	body	weight	may	be	required,	published	advice	on	cutting	patches	
available	(107)	
**	once	changed	from	overnight	to	all	day	use,	patches	to	be	changed	twice	weekly	
COCP	–	combined	oral	contraceptive	pill,	HRT,	hormone	replacement	therapy,	VTE	–	
venous	thromboembolism.	
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Figure	1	–	The	distribution	of	pubertal	timing	in	healthy	boys	and	girls.	These	data	
have	been	incorporated	into	UK	growth	charts	and	are	available	at	
www.growthcharts.rcpch.ac.uk.	Original	data	from	(108)	
	
	
	
	
	
	
	
Figure	2	Patterns	of	postnatal	gonadotropin	and	sex	steroid	secretion	in	boys	(a)	
and	girls	(b).	Gonadotropin	levels	start	to	increase	during	the	1st	week	of	life,	
peak	at	1–3	months,	and	then	decline	towards	the	age	of	6	months.	In	boys,	LH	
levels	are	higher	than	in	girls,	and	in	girls,	FSH	levels	predominate	and	remain	
elevated	until	3–4	years	of	age.	Testosterone	levels	in	boys	increase	following	
the	LH	levels	and	show	a	clear	peak	at	1–3	months	of	age,	but	in	girls,	estradiol	
levels	fluctuate,	probably	reflecting	ovarian	follicular	growth	and	atrophy.	
Estradiol	levels	in	girls	decline	in	the	2nd	year	of	life.	From	(7);	reproduced	with	
author	permission.	
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Figure	3.	Differential	diagnosis	of	delayed	puberty.		
Algorithm	for	the	evaluation	of	a	patient	with	delayed	puberty.	CDGP	-	constitutional	
delay	of	growth	and	puberty,	GI	-	gastrointestinal,	GH	-	growth	hormone,	GHD	-	GH	
deficiency,	PRL	-	prolactin,	IGF-1	-	insulin-like	growth	factor	1.	Reprinted	with	
permission	from	Palmert	MR,	Dunkel	L.	Clinical	practice.	Delayed	puberty.	N	Engl	J	
Med	2012;366:443-53	(4).		
	
																																																								
	
